NCT06219239
Safety and Efficacy of the Lentiviral Vector in Gene Therapy of Beta-thalassemia Patients
StatusTerminated
PhaseNot applicable
Primary completion
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 4 versions: 2 with changes below, 2 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Stopped Trial terminated Sponsor's reason: Suboptimal treatment response
- Eligibility criteria expanded, about 40 words
- Study completion date changed from estimate of Dec 31, 2026 to Dec 31, 2025
- Site details revised
- Study First Submitted
- Stopped: terminated, suspended or withdrawn
Endpoints
Primary
The number, frequency and severity of adverse events (AE) after reinfusion of KL003 drug products
Timeframe: within 6 months
The proportion of participants who meet the definition of transfusion independence (TI) for at least 6 months
Timeframe: Up to 24 months post transplant
Arms and interventions
KL003 cell injection Drug ProductExperimental
Traditional myeloablative conditioning regimen consists of Busulfan, which may increase the risk of irreversible pulmonary fibrosis, VOD, and infertility due to potential serious toxicity. In this study, we intend to use genetic hematopoietic stem cells (lentivirus transduction) transfusion with no conditioning regimen, which could avoid toxicity due to chemotherapy drugs.
Genetic: KL003 cell injection Drug Product
Sites
1 site in 1 country
- Institute of Hematology & Blood Diseases HospitalTianjin, Tianjin Municipality, China